

**Diabetic Kidney Disease Strategy Conference:
Implementing New Diabetic Kidney Disease Treatments - Time for Nephrologists to Act**

**Capital Hilton, Washington, DC
January 14, 2020**

Working Together to Address the Urgent and Unmet Needs in the Diagnosis and Treatment of People with Diabetic Kidney Disease

Agenda

- 7:30 AM** **Plated Breakfast**
- 8:00 AM** **Introductory Remarks**
Welcome and DKD-C introduction, patient perspective, description of optimal care for DKD
- | | |
|--------------------------|-------------------------|
| Susan Quaggin, MD | Northwestern University |
| Patrick Gee, PhD | Patient Advocate |
| Frank (Chip) Brosius, MD | University of Arizona |
- 8:30 AM** **New Therapies for Diabetic Kidney Disease: SGLT2 Inhibitors from CVOTs to Dedicated CKD Trials**
Overview of the success of SGLT2i trials and how to use these agents
- | | |
|-------------------|-----------------------|
| David Cherney, MD | University of Toronto |
|-------------------|-----------------------|
- 9:00 AM** **New Therapies for Diabetic Kidney Disease: GLP-1 Receptor Agonists and Non-Glycemic Agents**
Opportunities for other agents
- | | |
|----------------------|--------------------------|
| Katherine Tuttle, MD | University of Washington |
|----------------------|--------------------------|
- 9:30 AM** **State of DKD Care Implementation**
Best practices
- | | |
|------------------|--------------------------------|
| Adeera Levin, MD | University of British Columbia |
|------------------|--------------------------------|
- 10:00 AM** **Break**
- 10:15 AM** **Panel Discussion**
AAKH: Preventing Kidney Failure through Better Diagnosis, Treatment, and Incentives for Preventative Care
Provide an overview of AAKH with a focus on preventative care and its application to DKD
- | | |
|------------------------------|-------------------------|
| Moderator: Susan Quaggin, MD | Northwestern University |
|------------------------------|-------------------------|



11:15 AM Breakout Sessions - Perspectives on the Implementation of New Therapies for DKD
Review objectives and logistics for the breakout sessions

David Cherney, MD

University of Toronto

1. Nephrologists

Group 1 Moderator - Alan Kliger, MD Yale New Haven Health System

2. Nephrologists

Group 2 Moderator – Adeera Levin, MD University of British Columbia

3. Pharmaceutical

Moderator - Raymond Harris, MD Vanderbilt University Medical Center

4. Healthcare Delivery

Moderator – Chip Brosius, MD University of Arizona

5. Kidney Disease Patients

Moderator - Patrick Gee, PhD Patient Advocate

12:30 PM Plated Lunch

1:00 PM Breakout Session Reports on the Implementation of New Therapies for DKD

1:00 PM **Kidney Disease Patients**

1:10 PM **Nephrologists**

Group 1

Group 2

1:30 PM **Pharmaceutical**

1:40 PM **Healthcare Delivery**

1:50 PM Break

2:10 PM Next Steps: A Call to Action

Discuss the recommendations from each breakout group to create a platform for a DKD implementation strategy

Sue Quaggin, MD and the DKD-C Task Force

3:00 PM Adjourn